UTI MNC Fund
The scheme seeks to generate long term capital appreciation by investing predominantly in equity and equity related securities of multinational companies.
Growthvine rating: 3/5 — ranked #63 of 179 in category.
Fund basics
| Category | Equity: Thematic |
|---|
| NAV | ₹407.40 (as of 2026-08-21) |
|---|
| AUM | ₹2,765 Cr |
|---|
| Expense ratio | 1.69% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Karthikraj Lakshmanan |
|---|
| Exit load | 1% for redemption within 364 days |
|---|
Performance & risk
| 5-year annualised return | 9.46% |
|---|
| Sharpe ratio | 0.29 |
|---|
| Standard deviation | 14.51% |
|---|
| Max drawdown | -48.01% |
|---|
| Alpha | -2.13 |
|---|
| Beta | 0.9 |
|---|
Over 5 years, captured 36.7% of NIFTY CPSE's upside and 47.9% of its downside.
Market cap allocation
| Large cap | 37.5% |
|---|
| Mid cap | 26.4% |
|---|
| Small cap | 36.0% |
|---|
Concentration
| Top 5 holdings | 27.3% |
|---|
| Top 10 holdings | 41.2% |
|---|
| Total holdings | 60 |
|---|
Top holdings
- Maruti Suzuki India Ltd. — 8.4%
- Nestle India Ltd. — 5.9%
- Hindustan Unilever Ltd. — 5.0%
- NET CURRENT ASSETS — 4.7%
- PROCTER & GAMBLE HEALTH LIMITED — 4.5%
- Britannia Industries Ltd. — 3.4%
- Bosch Ltd — 3.4%
- Gland Pharma Limited — 3.3%
- HYUNDAI MOTOR INDIA LIMITED — 2.8%
- United Spirits Limited — 2.2%
Top sectors
- Automobile — 21.6%
- Pharma & Biotech — 16.4%
- Food Beverage & Tobacco — 11.5%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 1.0% | Q3 | #109 of 167 |
| 2025 | 3.4% | Q3 | #71 of 132 |
| 2024 | 16.7% | Q3 | #63 of 86 |
| 2023 | 22.6% | Q4 (Bottom) | #61 of 66 |
| 2022 | -1.4% | Q3 | #38 of 55 |